Literature DB >> 24125109

Right ventricular afterload and the role of nitric oxide metabolism in left-sided heart failure.

Matthias Dupont1, W H Wilson Tang.   

Abstract

Awareness has grown in recent years that right ventricular (RV) function is equally important as left ventricular (LV) function in the setting of left-sided heart disease. RV dysfunction can be the consequence of an increased afterload imposed by the failing LV. The concept of "afterload" is physically most correctly described by vascular input impedance. However, for clinical purposes, afterload is most often modeled to consist of 3 components; pulmonary vascular resistance (PVR), pulmonary arterial compliance (PAC), and characteristic impedance. Whereas PVR is historically most described, PAC (which represents the distensibility of the vasculature) has rapidly gained recognition for its prognostic ability in both pulmonary arterial hypertension and left-sided heart disease. Owing to the specific anatomy of the pulmonary circulation, PVR and PAC have an inverse hyperbolic relationship, which position can be shifted by varying wedge pressures. Knowledge of the afterload components helps one to understand how elevated left-sided filling pressures increase pulsatile load on the RV. An increase in resistive load (known as "reactive" or "out-of-proportion" pulmonary hypertension) ultimately complements the increase in pulsatile load. Perturbations in nitric oxide metabolism are thought to be crucial in this evolution and have therefore been sought as a major therapeutic target.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nitric oxide; pulmonary arterial compliance; pulmonary vascular resistance; right ventricular afterload

Mesh:

Substances:

Year:  2013        PMID: 24125109      PMCID: PMC3797419          DOI: 10.1016/j.cardfail.2013.08.004

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  97 in total

1.  Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure.

Authors:  Jay Ritzema; Richard Troughton; Iain Melton; Ian Crozier; Robert Doughty; Henry Krum; Anthony Walton; Philip Adamson; Saibal Kar; Prediman K Shah; Mark Richards; Neal L Eigler; James S Whiting; Garrie J Haas; J Thomas Heywood; Christopher M Frampton; William T Abraham
Journal:  Circulation       Date:  2010-02-22       Impact factor: 29.690

Review 2.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

3.  Evaluation of methods for estimation of total arterial compliance.

Authors:  N Stergiopulos; J J Meister; N Westerhof
Journal:  Am J Physiol       Date:  1995-04

Review 4.  The role of endothelium in the responses of vascular smooth muscle to drugs.

Authors:  R F Furchgott
Journal:  Annu Rev Pharmacol Toxicol       Date:  1984       Impact factor: 13.820

5.  Exhaled nitric oxide and exercise performance in heart failure.

Authors:  P Agostoni; M Bussotti
Journal:  Arch Physiol Biochem       Date:  2003-10       Impact factor: 4.076

6.  Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement.

Authors:  G F Mitchell; L A Moyé; E Braunwald; J L Rouleau; V Bernstein; E M Geltman; G C Flaker; M A Pfeffer
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

7.  Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management.

Authors:  D L Moraes; W S Colucci; M M Givertz
Journal:  Circulation       Date:  2000-10-03       Impact factor: 29.690

8.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

9.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

10.  Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure.

Authors:  M Usui; H Matsuoka; H Miyazaki; S Ueda; S Okuda; T Imaizumi
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.